Skip to content

Webinar: Orange Book listing sheets under the microscope

Related people
Image of Nicholas Mitrokostas
Nicholas Mitrokostas

Partner

Boston

View profile →

Image of Matthew Miner
Matthew Miner

Associate

Washington, D.C.

View profile →

27 April 2022

Preparing the Orange Book listing sheet (i.e., Form FDA 3542) for a U.S. patent is more than just checking the boxes. 

Generic drug companies have recently argued that statements made in those listing sheets could be used to preclude a patent owner in proving infringement; and the courts appear to be receptive to such arguments.

Listen to our discussion on recent caselaw that could implicate your Orange Book listing strategy and learn best practices and considerations to maximize the value of your pharmaceutical patents in the United States.